Kevin Feeley Sells 1,266 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 1,266 shares of GeneDx stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $53.77, for a total transaction of $68,072.82. Following the completion of the transaction, the chief financial officer owned 36,486 shares of the company’s stock, valued at $1,961,852.22. This represents a 3.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kevin Feeley also recently made the following trade(s):

• On Wednesday, April 29th, Kevin Feeley sold 392 shares of GeneDx stock. The stock was sold at an average price of $65.19, for a total transaction of $25,554.48.
• On Monday, March 16th, Kevin Feeley sold 5,706 shares of GeneDx stock. The stock was sold at an average price of $76.80, for a total transaction of $438,220.80.

GeneDx Stock Down 1.8%

Shares of NASDAQ:WGS opened at $59.92 on Friday. The company has a market capitalization of $1.78 billion, a PE ratio of -22.36 and a beta of 1.96. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx Holdings Corp. has a twelve month low of $32.21 and a twelve month high of $170.87. The firm has a 50 day simple moving average of $54.95 and a 200-day simple moving average of $90.19.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to analysts’ expectations of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same quarter in the prior year, the firm posted ($0.23) EPS. On average, equities analysts predict that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Institutional Trading of GeneDx

Several institutional investors and hedge funds have recently bought and sold shares of WGS. Jones Financial Companies Lllp raised its position in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in GeneDx in the 4th quarter valued at $27,000. Fifth Third Bancorp purchased a new stake in GeneDx in the 1st quarter valued at $31,000. Quarry LP raised its position in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares during the last quarter. Finally, Ramirez Asset Management Inc. purchased a new stake in GeneDx in the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on WGS shares. Wall Street Zen downgraded shares of GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Wells Fargo & Company restated an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Guggenheim reduced their price objective on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research report on Monday, February 23rd. Finally, Weiss Ratings downgraded shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, GeneDx has a consensus rating of “Moderate Buy” and an average price target of $96.43.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.